To evaluate the relevance of high-sensitivity assays for C-reactive protein (hs-CRP), as a sensitive marker of inflammation in asthmatic Iraqi patients. Additionally, correlations of serum levels of hs-CRP with patients' clinical characteristics and pulmonary function tests (PFTs) will be studied in a cross-sectional design. Materials and Methods: A random sample of 58 individuals were divided into a healthy (control) group (n=12) and two groups of adult patients with chronic stable asthma; (n=22) patients had been receiving inhaled corticosteroids (inhaled corticosteroid-positive, or ICS+VE group) for the past 2-3 months, and (n=24) steroid-naive patients (inhaled corticosteroidnegative, or ICS-VE, group). The selected individuals were subjected to hs-CRP measurement and PFTs. Results: The forced expiratory volume in one second (FEV 1 )/forced vital capacity (FVC) was measured in all subjects. In the ICS+VE and the ICS-VE groups, there was a significant correlation between the level of hs-CRP and FEV 1 /FVC with r: −0.891 and a p-value of<0.0005 for both groups. In the ICS-VE group, 78.5% had significant clinical symptoms, whereas only 22.7% of the ICS+VE group had significant clinical symptoms. This difference (for the prevalence of clinical symptoms) was significant with a chi-square value of 19.59, degree of freedom (df) =1, and p<0.0005. Conclusion: In the ICS-VE group, the level of hs-CRP was significantly higher than in both the ICS+VE group and the control group. The values of the PFTs were significantly lower in the ICS-VE group. The prevalence of clinical features was significantly higher in the ICS-VE group.
INTRODUCTION
Asthma is a chronic inflammatory disorder that results in recurrent episodes of breathing difficulties, and coughing, mainly at night or in the early morning. Boys are affected more commonly than girls. However, after puberty, females are affected slightly more.
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Asthma and C-reactive protein CRP is an acute-phase protein that can be simply and inexpensively measured to assess systemic inflammation. Standard CRP assays are not sensitive enough. Recently, assays for high-sensitivity C-reactive protein (hs-CRP) have become available. Many studies, concluded that hs-CRP levels are strongly associated with asthma.
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Evaluating the role of high-sensitivity C-reactive protein in asthmatic Iraqi patients and its correlation with parameters of patients' clinical characteristics and pulmonary function tests
Pathophysiology
The pathologic changes can be patchy, and without an extension to lung parenchyma. A characteristic finding is basement membrane thickening due to the sub epithelial deposition of collagen. Triggering factors, in susceptible patients, induce a hypersensitivity reaction with an early and/or late-phase pulmonary response. Both phases depend on allergen-specific immunoglobulin E (IgE). Bronchospasm in the late phase is mediated by the infiltrating cells' soluble factors. 2, 3, 5 
Clinical features
The symptoms are often triggered by exercise, allergen, or viral respiratory infections. The triad of wheezing, chest tightness, and shortness of breath is characteristic of asthma. One or more of these symptoms are reported in 90% of patients. The most characteristic finding of asthma is polyphonic expiratory wheezing, which requires respiratory effort. Over-inflation of the thoracic cage may be obvious.
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Diagnosis
The diagnosis is largely based on the presence of: characteristic triad of Symptoms; Day-to-day peak flow variability (>15% variability, or reversibility to inhaled beta-2 agonist); and other parameters of pulmonary function tests.
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Management
The main drugs for asthma are divided into bronchodilators and controllers. 3 
Bronchodilator therapy
These are: Beta-2 (B2)-adrenergic agonist, anticholinergics, and theophylline. B2-agonists are the most effective.
3,13-17
B2 agonist
A. short-acting B2 agonist These bronchodilators are the most effective in the symptoms of a sudden asthma attack. 3, [13] [14] [15] B. Long-acting B2 agonist Long-acting bronchodilators are used in conjunction with inhaled steroids to achieve long-term asthma control; if used alone, they can cause death. 15 
Anticholinergics
Anticholinergic agents have been used with beta-agonists for the emergency control of acute asthma.
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Theophyllines
Theophylline use has now fallen due to its safety profile.
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Controller therapies Inhaled corticosteroids
Inhaled corticosteroids are the main therapeutic modality for the long-term control of asthma. Their use has been associated with.
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Anti-leukotrienes
Leukotriene (LT) pathway inhibitors may substitute ICS in selected patients with mild asthma in which Steroids are not well-tolerated or not desired by the patient. Furthermore, anti-leukotrienes are useful as steroid-sparing agents in moderate-to-severe asthma. 1, 4, 6 Chromones They are very effective in trigger-induced asthma. Nedocromil was proven to be effective in children with chronic mild-to-moderate asthma.
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Anti-IgE
Omalizamub, a humanized anti-IgE antibody, is very effective in moderate-to-severe asthma by reducing exacerbations, improving lung function, and acting as a steroid-sparing agent. 
MATERIALS AND METHODS
Study sample
A random sample of 58 persons was divided into healthy(control) group (n=12) and two groups of adult patients with chronic stable asthma; 22 (n=22) patients had been receiving ICS(400-600 micrograms per day of chlorofluorocarbon [CFC]-beclomethasone dipropionate) (inhaled corticosteroid-positive, or ICS+VE group) for the past 2-3 months, and 24 (n=24) steroid-naive(inhaled corticosteroid-negative, or ICS-VE) patients had been treated with inhaled short-acting B2agonist (as required). The asthmatic patients were randomly selected from the outpatient clinic of the faculty of internal Medicine at Baghdad Medical City Teaching Complex. Individuals allocated to the control group were randomly selected from the medical and paramedical staff within the same hospital. None of the patients were smokers or had respiratory tract infections or exacerbations of asthma in the month prior to enrolment in the study. Individuals with diabetes mellitus, cardiac disease, malignant status, systemic disorders, or obesity with a body mass index (BMI) equal to or more than 30% and systemic disorders were excluded. The selected individuals were subjected to the measurement of hs-CRP and PFTs. Thorough history and clinical examination was also performed.
Study design A cross-sectional design Diagnostic criteria for asthma
The diagnosis of asthma was considered based on the clinical history of variable and intermittent airway obstruction combined with demonstration of airway variability measured using the reversibility test, which is defined as an increment of more than 12% (or 200 ml) of FEV1 after 15 minutes of administration of inhaled short-acting B2agonist (according to the British guidelines on the management of asthma).
Measurement of high-sensitivity C-reactive protein 9, 10, 22 Samples of peripheral venous blood were aspirated (5 milliliters), put in a plane tube, and centrifuged at 3000x g at 4 C for 5 minutes. The sera were placed in tightly sealable container and stored at −20 C (repeated freezing and thawing was avoided). 
Pulmonary function test
Pre-bronchodilatory FEV1 and FEV1/forced vital capacity (FVC) were measured using office spirometry in the pulmonary function test/outpatient clinic in Baghdad Teaching Hospital at the Baghdad Medical City Teaching Complex.
Statistical analysis
SPSS (Statistical Package for Social Sciences) version 19 was used for data input and analysis. For independent samples, a t-test was used to estimate the significance of difference between two continuous variables. Pearson's correlation coefficient was utilized to estimate the significance of relation between two continuous variables. A p value of less than 0.005 was considered significant. Table 1 shows the control group and the two groups of asthmatic patients; the inhaled corticosteroid-positive (ICS+VE) and inhaled corticosteroid-negative (ICS-VE) groups. Demographic parameters are shown together with the PFTs, and serum level of hs-CRP. In the control group, there was an equal sex distribution (6 males, 6 females); in the ICS+VE group, there were 8 males and14 females, and in the ICS-VE group, there were 11 males and 13 females. Disease duration in the ICS+VE and ICS-VE groups was almost comparable -15.1±3.9 years and 14.6±4.2 years, respectively. The FEV1/FVC in than ICS+VE group was significantly higher than in the ICS-VE group (73.5± 2.4 for ICS+VE vs. 67.9±2.3 for ICS-VE with p:< 0.0005). The serum hs-CRP in the ICS-VE group was significantly higher than that of the ICS+VE group (2.7±0.3mg/dl for ICS-VE vs. 1.3±0.1mg/dl for ICS+VE with p:< 0.0005, and 0.5± 0.2 mg/dl for the control group with p:< 0.0005). The serum hs-CRP in the ICS+VE group was significantly higher than that of the control group with p<0.05. Table 2 shows the correlations between serum hs-CRP and other parameters in the ICS+VE and the ICS-VE groups. There was a significant correlation between the serum level of hs-CRP and FEV 1 /FVC, with r: −0.891 and p: <0.0005 for both groups.
RESULTS
Concerning the clinical characteristics, the relation of significant clinical symptoms among the two asthmatic groups; in the ICS-VE group, 78.5% had significant clinical symptoms, whereas only 22.7% of the ICS+VE group had significant clinical symptoms. Table 3 illustrates the correlation of multiple variables among the ICS+VE group with their corresponding Confidence Interval (CI); the correlation between hs-CRP and FEV 1 /FVC had an inverse relation and was significant with a 99% confidence interval (CI). Tables 5 and 6 . Figure 1 shows the serum levels of hs-CRP among the three groups represented as mean ± standard deviation, 0.5 ± 0.2 mg/dl for control, 1.3 ± 0.1 for the ICS+VE group, and 2.7 ± 0.3 mg/dl for the ICS-VE group. 
DISCUSSION
In this cross-sectional study, the results have high levels of agreement with other studies, including those of: Kony et al., 8 Shimoda et al. 1 ,0 Razi et al., 9 and Kamath et al. 7 However, Ramirez et al.
22 study on patients with asthma, mostly of a mild severity, did not reveal any significant correlation between hs-CRP with asthma, wheezing, National Asthma Education and Prevention Program (NAEPP) control score, forced expiratory volume in one second (FEV1), or fractional exhaled nitric oxide (FeNO). [7] [8] [9] [10] 22 We studied the validity of hs-CRP in patients with asthma and its relationship to the clinical characteristics and the degree of airway inflammation. In our study, the sample was divided into three groups, the control, the steroid-positive (ICS+VE), and the steroid-negative (ICS-VE) groups. The age in the control group was less than that of the two asthmatic groups, with a value of 32 ± 4.3 years for the control group and 43.1 ± 6.2 years and 45.8 ± 4.9 years for the ICS-VE and ICS+VE groups, respectively. The disease duration in the ICS+VE group was 15.1 ± 3.9 years and 14.6 ± 4.2 in the ICS-VE group. The BMI was almost comparable among the three groups, at 25.6 ± 2.4 kg/m The FEV 1 /FVC was significantly lower in the ICS-VE group, with a value of 67.9 ± 2.3, in comparison to the higher value CRP in the ICS-VE group; the relationship is an inverse relationship. and a significant p value of < 0.0005, reflecting a higher degree of airway obstruction in the ICS-VE group due to a lack of inhaled corticosteroid use.
The symptoms of asthma (coughing, wheezing, chest tightness, and early morning awakening) were significantly higher in the ICS-VE group (77.3% with significant symptoms vs. 22.7% without symptoms), while in the ICS+VE group, symptoms were absent in the majority of patients (87.5% without symptoms vs. 12.5% with symptoms). The Pearson Chi-Square of asymptotic significance (2-sided) < 0.0005 was found.
CONCLUSION
In inhaled corticosteroid-negative patients (ICS-VE), the level of high-sensitivity C-reactive protein (hs-CRP) was (2.7 ± 0.3 mg/dl), which is significantly higher than that of both the inhaled corticosteroid-positive patients (ICS+VE) (1.3 ± 0.1 mg/dl) and the control group (0.5 ± 0.2 mg/dl), with a p value of < 0.0005. The level of hs-CRP in ICS+VE patients was significantly higher than that of the control group, with a p value of < 0.05. The values of the PFT (FEV 1 /FVC) as a measure of the degree of airway obstruction were significantly lower in the ICS-VE group in comparison to the ICS+VE group, correlating inversely with the values of hs-CRP levels. The prevalence of clinical signs and symptoms was significantly higher in the ICS-VE group in comparison to the ICS+VE group.
